The Vanquish system, developed by Minnesota-based Francis Medical and FDA-cleared in late 2025, uses thermal energy from sterile water vapor to target prostate tissue. By utilizing ultrasound and electromagnetic navigation, the device is designed to conform to specific prostate boundaries, protecting surrounding nerve bundles critical to sexual and urinary function.

Clinical results supporting the technology were recently published in The Journal of Urology following the VAPOR 2 study. Data from 110 patients showed that 91% achieved elimination of MRI-visible intermediate-risk disease after a single procedure. Beyond efficacy, the study reported high patient satisfaction, with 94% of participants confirming they were pleased with their choice of treatment one year later. For Dr. Su, the transition into his practice proved seamless, noting that the manageable learning curve allowed his team to perform procedures with confidence from the start.